EMA's Restriction Of Multaq Indication Could Spell Death Knell For The Drug In Europe

While giving it a positive risk/benefit balance, EMA says other anti-arrhythmic medicines should be considered before Sanofi's Multaq, potentially heralding its demise in Europe.